LLY vs NEOG
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
NEOG presents a stark contrast between a deteriorating income statement and a robust balance sheet. The Piotroski F-Score of 2/9 indicates significant fundamental weakness and poor operational trends, further evidenced by a -69.94% profit margin and declining revenue. However, the company maintains a strong liquidity position with a current ratio of 3.92 and low leverage (Debt/Equity 0.38), and the stock is currently trading at book value (P/B 0.99). While recent price momentum is bullish, the lack of earnings growth suggests this is a speculative turnaround play rather than a value investment.
Compare Another Pair
Related Comparisons
LLY vs NEOG: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Neogen Corporation (NEOG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.